Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
Breast Cancer
DRUG: Abemaciclib|DRUG: Standard Adjuvant Endocrine Therapy
Invasive Disease Free Survival (IDFS), IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause., Baseline to Recurrence or Death from Any Cause (Up to 32 Months)
IDFS for Participants With Ki-67 Index â‰¥20%, Outcome data will be provided after the study is completed., Baseline to Recurrence or Death from Any Cause (Approximately 10 Years)|Distant Relapse-Free Survival (DRFS), Distant relapse-free survival is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first., Baseline to Distant Recurrence or Death from Any Cause (Up to 32 Months)|Overall Survival (OS), Outcome data will be provided after the study is completed., Baseline to Death from Any Cause (Approximately 10 Years)|Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib, Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib, Day 1 (2 hours post-dose), Days 30, 60, 90 post-dose|Change From Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B), Outcome data will be provided after the study is completed., Baseline, Follow Up (Approximately 3 Years)|Change From Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES), Outcome data will be provided after the study is completed., Baseline, Follow Up (Approximately 3 Years)]|Change From Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), Outcome data will be provided after the study is completed., Baseline, Follow Up (Approximately 3 Years)]|Change From Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L), Outcome data will be provided after the study is completed., Baseline, Follow Up (Approximately 3 Years)]
The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.